Key Takeaway: MapLight Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference on November 18th in London. The management team will present and host one-on-one meetings. The company focuses on developing therapies for central nervous system disorders, leveraging its discovery platform to target specific neural circuits.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in a notable investor conference
Opportunity for 1x1 meetings with management
Focus on central nervous system disorders
Potential for innovative therapies
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~18 mo
Medium dilution risk
Lead asset
ML-007C-MA
Phase 2 · Schizophrenia
Full Press Release Details
SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
Event: 2026 Jefferies Global Healthcare Conference (London, UK) Date: Wednesday, November 18th Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.